United States· US:60760-748_526982bc-f7b7-0c37-e063-6394a90a6d6f
Tivicay
A dolutegravir product containing dolutegravir sodium, registered in United States by ST. MARY'S MEDICAL PARK PHARMACY. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Dolutegravir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AJ03 (dolutegravir), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Dolutegravir · ATC J05AJ03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dolutegravir costs, country by country.
Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dolutegravir · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- CH Switzerland$25.85
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DOLUTEGRAVIR SODIUM
- Manufacturer
- ST. MARY'S MEDICAL PARK PHARMACY
- Country
- United States (US)
- ATC code
- J05AJ03
- ATC class
- Dolutegravir
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1160760748077 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60760-748-07)
- ndc1160760-748-07
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
94 interactions on record for dolutegravir.
Graded by severity as the source publishes them — 42 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dolutegravir · interactions on record
94 records
- 42 severe
- 3 moderate
- 49 minor
Most severe, free to view
- Magnesium carbonateA02AA01severe
- Magnesium oxideA02AA02severe
- Magnesium hydroxideA02AA04severe
- Kombinationen von AluminiumsalzenA02AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dolutegravir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDOLUTEGRAVIR TEVATeva GmbH, Ulm
- SwedenDogrivio 50 mg Filmdragerad tablettElpen Pharmaceutical Co. Inc
- BelgiumDovato 50 mg - 300 mgViiV Healthcare
- FinlandTivicayViiV Healthcare BV
- IrelandDolutegravir Teva 50 mg film-coated tabletsTEVA GmbH
- NetherlandsDolutegravir Teva 50 mg, filmomhulde tablettenTeva GmbH
- NorwayTivicayViiV Healthcare BV (1)
- PolandTivicayViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Cyprus · Dogrivio
- Iceland · Tivicay
- Liechtenstein · Tivicay
- Norway · Dolutegravir Teva, Tivicay
- Sweden · Dogrivio, Dolutegravir Elpen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/772153ad-9dbc-412a-9c34-093b3203d3bf GET /v1/drugs/772153ad-9dbc-412a-9c34-093b3203d3bf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "50",
"substance": "DOLUTEGRAVIR SODIUM",
"productndc": "60760-748",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA204790",
"marketing_category": "NDA"
}See everything about dolutegravir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.